Author:
Nitta Kosaku,Hanafusa Norio,Akiyama Kenichi,Kawaguchi Yuki,Tsuchiya Ken
Abstract
Chronic kidney disease—mineral and bone disorder (CKD-MBD) is a systemic disorder that increases the risk of morbidity and mortality in dialysis patients. CKD-MBD is highly prevalent in dialysis patients, and appropriate treatment is important for improving their outcomes. Inorganic phosphate, fibroblast growth factor 23, parathyroid hormone, and calciprotein particles are markers for critical components and effectors of CKD-MBD, and higher circulating levels of these markers are linked to cardiovascular diseases. In this short review, we focus on the pathogenesis and management of CKD-MBD in CKD patients, especially those on dialysis therapy, and discuss the prospects for improving the management in CKD patients, including those on dialysis.
Reference81 articles.
1. Overview of renal bone disease: Causes of treatment failure, clinical observations, the changing pattern of bone lesions, and future therapeutic approach;Llach;Kidney Int. Suppl.,2003
2. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO);Moe;Kidney Int.,2006
3. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group (2009). KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl., 113, S1–S130.
4. Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients;Taniguchi;Ther. Apher. Dial.,2013
5. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study;Block;Am. J. Kidney. Dis.,1998
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献